pancreatic cancer

Pancreatic Cancer in 2014

Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in men and women in the United States. This year, about 46,000 people in this country will be diagnosed with pancreatic cancer, and more than 39,000 will die of the disease. The ASCO Post recently spoke with Margaret A....

pancreatic cancer

Study Sheds Light on Factors That May Contribute to Pancreatic Cancer

New research that provides a better understanding of pancreatic cancer may help identify individuals at increased risk. The findings were recently published early online in Cancer.1 Pancreatic cancer is usually detected at a very late stage and has a 5-year survival rate of less than 5%....

pancreatic cancer

Mitochondrial Respiration as Target in KRAS-Mutant Pancreatic Cancer

Targeting of oncogenes can produce tumor shrinkage, but the frequency of relapse indicates that a population of tumor cells survives oncogene inhibition. In a study in a KRAS-mutant pancreatic ductal adenocarcinoma mouse model reported in Nature, Viale and colleagues found that a subpopulation of...

pancreatic cancer

WEE1 Inhibition Sensitizes Pancreatic Cancer to PARP Inhibitor Radiosensitization

In a study reported in Clinical Cancer Research, Karnak and colleagues found that WEE1 kinase inhibition increased the sensitivity of pancreas cancer to the radiosensitizing effects of poly(ADP-ribose) polymerase (PARP) inhibition. Treatment of human pancreatic cancer AsPC-1 and MiaPaCa-2 cells...

pancreatic cancer

Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib as a first-line treatment in combination with paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Necuparanib is a novel oncology drug candidate engineered from...

pancreatic cancer

Choice for Metastatic Pancreatic Cancer: FOLFIRINOX or Gemcitabine/Nab-Paclitaxel?

The choice between FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) vs the combination of gemcitabine and nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) for first-line treatment of metastatic pancreatic cancer is not much of a contest, judging by a discussion of...

Pancreatic Cancer

Modified Nab-Paclitaxel/Gemcitabine in Pancreatic Cancer: Efficacious, Less Toxic, Less Costly

A less intensive regimen of nab-paclitaxel (Abraxane) plus gemcitabine appears to be as efficacious as the standard regimen in first-line treatment for metastatic pancreatic cancer, but less toxic and far less expensive, according to a study that earned a Merit Award at the 2015 Gastrointestinal...

pancreatic cancer

Pancreatic Cancer: Latest Drug Development Hits and Misses

Targeting one of the deadliest cancers and seeking to fill an unmet need, drug development in pancreatic cancer is an area of high interest. This was certainly the case at the 2015 Gastrointestinal Cancers Symposium, where results were impressive for some novel agents but disappointing for several...

pancreatic cancer

FOLFIRINOX Plus Radiation Renders Some Locally Advanced Pancreatic Cancer Patients Resectable

Investigators from Moffitt Cancer Center in Tampa, Florida, have reported an approach to pancreatic cancer that downstages some locally advanced patients to borderline resectable status and achieves a negative surgical margin rate exceeding 96%. The study earned a Merit Award at the 2015...

gynecologic cancers
pancreatic cancer

Human Reovirus Formulation Gets Orphan Drug Designation in Ovarian and Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Oncolytics Biotech’s proprietary formulation of the human reovirus (Reolysin) for the treatment of ovarian and pancreatic cancer. The reovirus’s primary mode of activity is to infect and selectively target tumors...

Colorectal Cancer
Pancreatic Cancer
Gastrointestinal Cancer

New Data Reported in Colorectal, Gastric, and Pancreatic Cancers

The 2015 Gastrointestinal Cancers Symposium, held January 15–17 in San Francisco, attracted almost 4,000 attendees, who heard or viewed data from nearly 800 scientific abstracts and lectures. Here are our summaries of some of the many important developments from the meeting. Bevacizumab Plus...

Pancreatic Cancer

Heal Thy Patient … Reflections on the Human Side of Medicine

The first time I met Mrs. X and her husband was to discuss the surgical treatment options for pancreatic cancer. She had just been diagnosed with pancreatic cancer at her local hospital and was being referred to a tertiary care center for operative management. Mrs. X and her husband were no...

Lung Cancer
Pancreatic Cancer
Geriatric Oncology

Chemotherapy Trial Results Overestimate Survival for Elderly Medicare Patients With Lung and Pancreatic Cancers

Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Elizabeth B. Lamont, MD, MS, of...

Pancreatic Cancer

FDA Grants Fast Track Designation to Evofosfamide for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (TH-302), administered in combination with gemcitabine, for previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. Evofosfamide is an...

Pancreatic Cancer
Issues in Oncology

Many Miles to Go: Targeted Treatment Based on Whole-Genome Sequencing

The ability to do genomic analysis of patients’ tumors holds great promise for revolutionizing cancer treatment, and genomics has already made some great strides. However, the Individualized Molecular Pancreatic Cancer Therapy ­(IMPaCT) trial is a cautionary tale about the hurdles involved in...

Skin Cancer
Breast Cancer
Multiple Myeloma
Leukemia
Colorectal Cancer
Prostate Cancer
Pancreatic Cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2015 Updates

For 2 decades, the NCCN Guidelines® have been recognized as the standard of cancer care in the United States, combining evidence, experience, and choice, so that multidisciplinary cancer treatment teams—including patients—are empowered to make informed decisions about cancer care,” said Robert W....

Pancreatic Cancer

Novel Enzyme Improves Outcomes in Subset of Patients With Pancreatic Cancer

Patients with stage IV pancreatic cancer who received a novel enzyme along with standard chemotherapy experienced a doubling in progression-free survival, compared to those given chemotherapy alone, in a study presented at the 2015 ASCO Annual Meeting.1 Response rates and median duration of...

Pancreatic Cancer

FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration has approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. The effectiveness of...

Pancreatic Cancer

Irinotecan Liposome Injection Plus Fluorouracil/Leucovorin to Treat Patients With Metastatic Pancreatic Cancer

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On October 22, 2015, irinotecan liposome injection (Onivyde)...

Pancreatic Cancer

Clinical Trials Actively Recruiting Patients With Pancreatic Cancer

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with pancreatic cancer. The trials are investigating preoperative rehabilitation; chimeric antigen receptors; T-cell transplants; combination chemotherapy; chemoradiotherapy; ...

pancreatic cancer

Improved Overall Survival With Addition of Nanoliposomal Irinotecan to Fluorouracil/Leucovorin in Metastatic Pancreatic Cancer

In the phase III NAPOLI-1 trial reported in The Lancet, Wang-Gillam et al found that the addition of nanoliposomal irinotecan (Onivyde) to fluorouracil (5-FU) and folinic acid (leucovorin) resulted in improved overall survival in patients with metastatic pancreatic ductal cancer who had received...

issues in oncology
pancreatic cancer

Phase II Study Shows No Benefit of Adding Vismodegib to Gemcitabine in Metastatic Pancreatic Cancer

In a phase II study reported in the Journal of Clinical Oncology, Catenacci et al found no benefit of adding vismodegib (Erivedge) to gemcitabine in patients with metastatic pancreatic cancer. Sonic hedgehog (SHH), an activating ligand of the smoothened receptor (SMO) inhibited by vismodegib, has...

pancreatic cancer
issues in oncology
issues in oncology
issues in oncology

Study Advances Potential Test to Distinguish Precancerous Pancreatic Cysts From Harmless Ones

In a retrospective analysis of data from 130 patients with pancreatic cysts, scientists at Johns Hopkins have used gene-based tests and a fixed set of clinical criteria to more accurately distinguish precancerous cysts from those less likely to do harm. The findings may eventually help some...

pancreatic cancer

Preclinical Study Reveals Why Chemotherapy May Be Compromised in Patients With Pancreatic Cancer

A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many patients with pancreatic cancer and perhaps point to new approaches to treatment, including enhancing gemcitabine's ability to stop tumor growth. The MD...

pancreatic cancer
issues in oncology

Only 1 in 5 U.S. Patients With Pancreatic Cancer Gets Key Blood Test at Diagnosis

Only 1 in 5 patients with pancreatic cancer in the United States receives a widely available, inexpensive blood test at diagnosis that can help predict relative outcome (compared to others with the same disease stage) and guide treatment accordingly, a Mayo Clinic study showed. People who test...

pancreatic cancer

Immunotherapy for Pancreatic Cancer Boosts Survival by More Than 75% in Preclinical Models

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy—even when used without chemotherapy or radiation—can boost survival from pancreatic cancer by more than 75%. The findings are promising, and human clinical...

pancreatic cancer

FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration today approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. According to the National...

pancreatic cancer

Ruxolitinib-Capecitabine May Benefit Patients With Gemcitabine-Pretreated Metastatic Pancreatic Cancer With Systemic Inflammation

In a randomized phase II trial reported in the Journal of Clinical Oncology, Hurwitz et al found no significant survival benefit of adding the JAK1/JAK2 inhibitor ruxolitinib (Jakafi) to capecitabine in patients with advanced pancreatic adenocarcinoma who had treatment failure with gemcitabine....

pancreatic cancer

Pancreatic Cancer Action Network and AACR Invite Applications for 2016 Research Grants

The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer. Two grant mechanisms, the Pathway to Leadership Grant and the Career...

issues in oncology
pancreatic cancer
issues in oncology

MicroRNA Panel Shows Early Potential as Biomarker of Pancreatic Precancers

Assessing blood plasma levels of certain microRNAs (miRNAs) distinguished individuals with noninvasive pancreatic precancers from healthy individuals and discriminated between patients with high-risk and low-risk neoplasms, according to a preliminary, proof-of-principle study published by...

issues in oncology
pancreatic cancer
issues in oncology
issues in oncology

Study Identifies Genes Associated With Improved Survival for Patients With Pancreatic Cancer

A multi-institutional study has found a new set of genes that may indicate improved survival after surgery for patients with pancreatic cancer. The study also showed that detection of circulating tumor DNA in the blood could provide an early indication of tumor recurrence. In conjunction with the...

issues in oncology
pancreatic cancer

Researchers Identify Nerve-Guiding Protein That May Be Associated With Pancreatic Cancer Metastasis

Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease metastasizes in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer and were published by Foley et...

issues in oncology
pancreatic cancer
issues in oncology

Proteins Found in Urine May Serve as Biomarker for Early-Stage Pancreatic Cancer

A team of researchers at Barts Cancer Institute­­–Queen Mary University of London has discovered a combination of three proteins found at high levels in urine that can accurately detect early-stage pancreatic cancer. The discovery could lead to a noninvasive, inexpensive test to...

solid tumors
pancreatic cancer
prostate cancer
bladder cancer

Analysis Suggests Use of Pioglitazone for Diabetes May Increase Risk of Prostate and Pancreatic Cancers But Not Bladder Cancer

Available data suggest an increased risk of bladder cancer with pioglitazone treatment for diabetes. In an analysis of Kaiser Permanente Northern California data reported in JAMA, Lewis et al found no significantly increased risk of bladder cancer in patients with diabetes ever using pioglitazone....

pancreatic cancer
prostate cancer

Study Identifies Mechanism Fueling Growth of Pancreatic and Prostate Cancer Cells

UCLA Jonsson Cancer Center scientists have identified a new mechanism that delivers a key substance that fuels the growth of pancreatic and prostate cancer cells, a finding that offers new hope in the fight against two of the deadliest forms of the disease. Their findings were published by...

issues in oncology
pancreatic cancer
issues in oncology
issues in oncology

Protein-Enriched Exosome Useful for Early Diagnosis of Pancreatic Cancer

A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential noninvasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study completed by University of Texas MD...

pancreatic cancer

Dutch Study Indicates No Survival Benefit of Adding Metformin to Gemcitabine-Erlotinib in Advanced Pancreatic Cancer

In a Dutch phase II study reported in The Lancet Oncology, Kordes et al found that adding metformin to gemcitabine-erlotinib (Tarceva) did not improve overall survival in patients with advanced pancreatic cancer. Study Details In the double-blind study, 121 patients from four centers in the...

colorectal cancer
solid tumors
pancreatic cancer
supportive care

ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy

The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....

pancreatic cancer

Boosted Radiation Dose May Make Some Pancreatic Cancers Resectable

Because of their location, cancers on the pancreas often invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more difficult—sometimes impossible....

hematologic malignancies
hepatobiliary cancer
pancreatic cancer
issues in oncology

Abdominal Blood Clots May Indicate Undiagnosed Cancer

New research published by Søgaard et al in Blood found that blood clots in the abdominal veins might be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer. Clotting and Cancer Risk Compared to...

pancreatic cancer
survivorship

National Cancer Database Analysis Identifies Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma

In an analysis reported in JAMA Surgery, Paniccia et al identified patient and treatment characteristics that were associated with survival of at least 10 years after diagnosis of invasive pancreatic ductal adenocarcinoma, including lower positive lymph node ratio, receipt of adjuvant chemotherapy, ...

palliative care
pancreatic cancer
issues in oncology

Two Studies Highlight Benefit of Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Cancer

Two studies from researchers at Johns Hopkins Kimmel Cancer Center add to preliminary evidence that high-dose radiation treatment, or stereotactic body radiotherapy, appears to be safe and as effective as standard radiation treatment for certain patients with locally advanced pancreatic cancer....

pancreatic cancer

Pazopanib Plus Octreotide Active in Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

In a phase II study reported in The Lancet Oncology, Phan et al found that the VEGFR-1, -2, -3 inhibitor pazopanib (Votrient) plus depot octreotide produced responses in patients with advanced well-differentiated neuroendocrine tumors. No responses were observed in patients with carcinoid tumors....

palliative care
pancreatic cancer
supportive care

German Trial Shows Reduced Risk of Venous Thromboembolism With Prophylactic Enoxaparin in Ambulatory Patients With Advanced Pancreatic Cancer

In the German CONKO-004 trial reported in the Journal of Clinical Oncology, Pelzer et al found that prophylactic treatment with the low-molecular-weight heparin enoxaparin reduced the risk of symptomatic venous thromboembolic events in ambulatory patients receiving first-line chemotherapy for...

pancreatic cancer
issues in oncology

Germline BRCA Mutations Found in Almost 5% of Patients With Pancreatic Adenocarcinoma

In a study reported in the Journal of Clinical Oncology, Holter et al found that 4.6% of a large clinic population of patients with pancreatic adenocarcinoma harbored pathogenic germline BRCA mutations. The study involved analysis of 306 unselected, consecutive, incident patients with pancreatic...

pancreatic cancer

FDA Grants Fast Track Designation to Evofosfamide for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (TH-302), administered in combination with gemcitabine, for previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. Evofosfamide is an...

pancreatic cancer

Weak Sunlight Exposure May Be a Risk Factor in Pancreatic Cancer

Researchers at University of California San Diego School of Medicine recently found that pancreatic cancer rates are highest in countries with the least amount of sunlight. These findings were published by Garland et al in The Journal of Steroid Biochemistry and Molecular Biology. “If...

pancreatic cancer

AACR 2015: Metformin Use May Not Improve Pancreatic Cancer Survival

Metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma in a retrospective cohort study presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract LB-183). “The diabetes drug metformin is being used in some cancer treatment...

palliative care
gynecologic cancer
pancreatic cancer
solid tumors

AACR 2015: Investigational CART-meso Immunotherapy Feasible for Patients With Advanced Cancers

Patients with advanced cancers who received mesothelin-directed chimeric antigen receptor–modified T cells (CART-meso), a type of investigational adoptive immunotherapy, tolerated the treatment well, and there was evidence that the infused immune cells persisted in the patients’ blood...

pancreatic cancer

Improved Quality Metrics for Robotic Pancreaticoduodenectomy With Increased Performance

In a retrospective single-institution study reported in JAMA Surgery, Boone et al found significant improvements in blood loss, incidence of conversion to open surgery, pancreatic fistula incidence, and operative time with increased number of patients treated with robotic pancreaticoduodenectomy....

Advertisement

Advertisement

;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.